Cervical cancer refers to the malignant transformation of cervical epithelial or glandular cells, primarily attributed to persistent infection with high-risk human papillomavirus (HPV) genotypes. Recurrent or metastatic cervical cancer is characterized by an unfavorable prognosis and a high mortality rate. Although incorporating the anti-angiogenic agent bevacizumab into treatment protocols has led to enhanced survival rates, a significant number of patients with disease progression following initial platinum-based chemotherapy have limited therapeutic options. This paper aims to provide an overview of the current progress in cervical cancer treatment strategies, with a focus on the most relevant, potentially practice-changing results of recent phase III clinical trials.
No takes yet. Share an insight, caveat, or question.
Braun et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: